

| Drug Name | Mechanism of Action | T2DM Mechanisms | | |
|---------------|---|-----------------------------|---------------------------------|---------------------------------------|
| | | Improve insulin sensitivity | Inhibit hepatic gluconeogenesis | Inhibit pancreatic glucagon secretion |
| Canagliflozin | SGLT2 inhibitors | - | - | - |
| Dapagliflozin | SGLT2 inhibitors | - | - | - |
| Empagliflozin | SGLT2 inhibitors | - | - | - |
| Metformin | Biguanide | ✓ | ✓ | - |
| Pioglitazone | Thiazolidinediones, PPAR- γ Activation | ✓ | - | - |
| Resmetirom | THR- β agonist | ? | ? | ? |
| Semaglutide | GLP-1 receptor agonist | - | - | ✓ |
| Tirzepatide | Dual GLP-1 receptor and GIP receptor agonist | ✓ | - | ✓ |

| D Impact | | | | Liver Impact | |
|---------------------|---|--------------------|---------------------------------|----------------|---------------------|
| bit gon- tion | Increase glucose- dependent insulin secretion | Reduce appetite | Promote glucose excretion | Improve NAS | Improve Fibrosis |
| | - | - | ✓ | ✓ | ✓ |
| | - | - | - | - | - |
| | - | - | - | ✓ | Variable |
| | ? | ? | ? | ✓ | ✓ |
| ✓ | ✓ | ✓ | - | ✓ | - |
| ✓ | ✓ | ✓ | - | ✓ | ✓ |